Lactiplantibacillus plantarum 299v

Lactiplantibacillus plantarum 299v is a specific commercial strain isolated from healthy human intestinal mucosa with extensive clinical documentation in irritable bowel syndrome, iron absorption enhancement, and inflammation modulation. The strain is the basis of the ProViva and ProbiMage brands.

Supplied as a freeze-dried powder with viability between 100 and 500 billion CFU per gram at release. The strain demonstrates exceptional adhesion to human intestinal mucus via mannose-binding adhesins and tolerates the full gastrointestinal stress sequence at clinically relevant survival rates.

Off-white to pale yellow free-flowing powder with a faintly fermented note. Particle size suitable for capsule, sachet, and powdered beverage applications.

We supply food-grade Lactiplantibacillus plantarum 299v commercial-equivalent strain from manufacturers in China holding ISO 22000, FSSC 22000, Halal, Kosher, and other certifications relevant to probiotic strain production.

Common market grades include 100, 200, and 500 billion CFU per gram freeze-dried powders, microencapsulated grades for beverage applications, and high-iron-bioavailability synbiotic blends with vitamin C and iron salts. Bulk and reduced-MOQ shipments with batch-level COA covering viable count, strain identity, moisture, heavy metals, and pathogen panel.

L. plantarum 299v was isolated from healthy human intestinal mucosa by researchers at the University of Lund in Sweden during the 1980s and deposited at Deutsche Sammlung von Mikroorganismen under accession DSM 9843. The strain is patented and licensed by Probi AB and marketed under the ProViva and ProbiMage brands in Northern Europe.

The strain is distinguished by uniquely strong adhesion to the human intestinal mucus layer via mannose-specific adhesins, and by a broad fermentation profile that includes plant-derived pentose sugars, supporting non-dairy and Halal production chains.

Industrial production uses MRS-derived proprietary media under controlled anaerobic conditions, with biomass harvest, cryoprotectant blending, and lyophilization to residual moisture below 5 percent. Strain identity is verified by pulsed-field gel electrophoresis matching the deposited DSM 9843 pattern.

Regulatory status includes Qualified Presumption of Safety listing in the European Union and acceptance under Codex Alimentarius standards for probiotic-fortified foods.

Clinical evidence supports the strain for irritable bowel syndrome symptom reduction (bloating, pain, and flatulence), enhancement of iron absorption from non-heme sources when co-administered with iron salts and vitamin C, and modulation of systemic inflammation markers in metabolic syndrome.

• Capsules and tablets for irritable bowel syndrome symptom support
• Iron absorption enhancement supplements (synbiotic with iron salts)
• Functional plant-based fermented beverages
• Adult gut microbiome restoration products
• Cardiometabolic and inflammation-targeted formulations
• Pregnancy and maternal nutrition supplements
• Multi-strain adult probiotic stacks
• Sports nutrition and immune support
• Senior nutrition for gut barrier and inflammation